For M&A transactions in the first half of 2022, over 75% of target Healthtech companies were based in the US, with 12% in Europe, 5% in Canada, and the remaining 8% distributed among other countries. 


The vast majority of buyers in the first half of 2022 were based in North America – with 76% from the US and 8% from Canada.